{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["CF_E"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":0,"defined_names":0,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"CF_E","index":0,"n_rows":52,"n_cols":6,"rows_kept":52,"cut":false,"hidden":false,"merged":[[2,1,2,2]]}
[]
[null,"Consolidated statement of cash flows (IFRS)"]
[null,"from 1 October 2019 to 30 September 2020"]
[null,null,"2019/20\n1 Oct 19 to 30 Sep 20","2018/19\n1 Oct 18 to 30 Sep 19"]
[null,null,"€ k","€ k"]
[null,"Cash flows from operating activities:"]
[null,"Consolidated profit",123421,160579]
[null,"Adjustments to reconcile consolidated profit to net cash \nprovided by / (used in) operating activities"]
[null,"Income taxes",55296,69279]
[null,"Interest income / expenses",26432,6409]
[null,"    Result from other investments ",0,-34]
[null,"Result from the change in fair value of contingent purchase price obligations",-23131,0]
[null,"Depreciation and amortisation",60425,48370]
[null,"Gains/losses on disposal/depreciation of fixed assets ",94,719]
[null,"    Dividends received",0,34]
[null,"Interest received",1428,1774]
[null,"Interest paid",-1365,-1903]
[null,"Refunded income taxes",11991,6003]
[null,"Income taxes paid",-70955,-71073]
[null,"Changes in working capital:"]
[null,"Trade receivables",54177,-20607]
[null,"Inventories",-28421,-11349]
[null,"Other assets",-2528,6542]
[null,"Trade payables",-25171,14695]
[null,"Provisions and financial liabilities",-7015,14564]
[null,"Other liabilities",3849,-4368]
[null,"Total adjustments",55106,59055]
[null,"Net cash provided by / (used in) operating activities",178527,219634]
[null,"Cash flows from investing activities::"]
[null,"Investment in property, plant and equipment",-29325,-20348]
[null,"Investment in other intangible assets",-15662,-26363]
[null,"Proceeds from fixed assets",128,887]
[null,"Proceeds from sale of investments",163,149]
[null,"Payments for other loans",0,-177]
[null,"Purchase of investments",0,-4857]
[null,"Investments/divestitures in securities",0,1196]
[null,"Purchase of shares in affiliated non-consolidated companies",-25,0]
[null,"Purchase of shares in affiliated consolidated companies, net of cash acquired",-27227,-96333,null,"incl sale of subsidiary Hexavision"]
[null,"Net cash provided by / (used in) investing activities",-71947,{"$f":"SUM(D30:D38)","v":-145846}]
[null,"Cash flows from financing activities:"]
[null,"Proceeds from / (repayment of) current liabilities to banks",27,-103]
[null,"(Increase)/decrease in treasury receivables",-50329,11619]
[null,"Increase/(decrease) in treasury payables",1554,-1672]
[null,"Repayment of leasing liabilities",-16077,-13663]
[null,"    Dividend payments to shareholders of Carl Zeiss Meditec AG",-58136,-49192]
[null,"Dividend payments to non-controlling interests",0,-5626]
[null,"Net cash provided by / (used in) financing activities",{"$f":"SUM(C41:C46)","v":-122961},{"$f":"SUM(D41:D46)","v":-58637}]
[null,"Effect of exchange rate fluctuation on cash and cash equivalents",-1056,810]
[null,"Net increase/(decrease)  in cash and cash equivalents",-17437,15961]
[null,"Cash and cash equivalents, beginning of reporting period",22639,6678]
[null,"Cash and cash equivalents, end of reporting period",{"$f":"+C49+C50","v":5202},{"$f":"+D49+D50","v":22639}]
[null,"The following notes are an integral part of the audited consolidated financial statements."]